Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) and Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
Volatility and Risk
Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Zenas BioPharma and Arcturus Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
| Arcturus Therapeutics | 1 | 3 | 6 | 1 | 2.64 |
Institutional & Insider Ownership
94.5% of Arcturus Therapeutics shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Zenas BioPharma and Arcturus Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zenas BioPharma | $10.00 million | 191.85 | -$377.74 million | ($8.47) | -3.59 |
| Arcturus Therapeutics | $42.35 million | 3.71 | -$65.78 million | ($2.81) | -1.97 |
Arcturus Therapeutics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Zenas BioPharma and Arcturus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zenas BioPharma | N/A | -99.99% | -58.06% |
| Arcturus Therapeutics | -143.80% | -36.55% | -28.40% |
Summary
Arcturus Therapeutics beats Zenas BioPharma on 11 of the 14 factors compared between the two stocks.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
